Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"Annexin-A1"”.
-
Annexin A1 im chronischen Nierenversagen
… Das anti-inflammatorische Protein Annexin A1 und sein Rezeptor Formyl-Peptid Rezeptor 2 (FPR2) wurden in verschiedenen Organsystemen mit der Regulation von Fibroblastenaktivität in Verbindung gebracht, jedoch wurden ihre Expression und Funktion bei renalen fibrotischen Erkrankungen …
-
PROTEOMICS INSIGHTS INTO MOLECULAR MECHANISMS OF TRIPTOLIDE AGAINST COLORECTAL CANCER
… and proteomic approaches. Peroxiredoxin I and Annexin A1 were validated to be the direct binding targets of triptolide. Proteomics approaches allows the study of altered proteins by triptolide and binding targets of triptolide at a global level, which provides some insight into the mechanism of …
-
Analisi Molecolare del Melanoma
… S27 a precursor, the basic form of protein DJ-1, annexin a1, proliferation associatedvprotein 2g4, isoform alfa-enolase of alfa-enolase, protein disulfide-isomerase precursor and elongation factor 2 werevmore strongly expressed in A375 cells compared with melanocytes. In 526 cells, 60s acidic …
-
Caratterizzazione proteomica di fluidi e tessuti in diverse condizioni fisio-patologiche
… family A member 1, two proteoforms of annexin A1, and keratin type 1 cytoskeletal 13), and several over-expressed proteins in adults (fatty acid-binding protein, S100A6, S100A7, two proteoforms of S100A9, several proteoforms of prolactin-inducible protein, Ig kappa chain, two …
-
Role of adipose tissue as an endocrineorgan in systemic inflammation
… regulated anti‐inflammatory protein, annexin A1 (AnxA1) and its role in fat tissue function; and Study 3: a double‐blind cross‐over randomised trial in 15 borderline metabolic syndrome males investigating the effect of a supplemental antiinflammatory agent, resveratrol (250 mg/day for …
-
Targeting the formyl peptide receptor 1 for treatment of glioblastoma
Background and Aims Gliomas account for over half of all primary brain tumours and have a very poor prognosis, with a median survival of less than two years. There is an urgent and unmet clinical need to develop new therapies against glioma. Recent reports have indicated the overexpression of FPR1 …